Enhydrin suppresses the malignant phenotype of GBM via Jun/Smad7/TGF-β1 signaling pathway

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Glioblastoma (GBM) is an aggressive brain tumor driven by cancer cell proliferation, infiltration, and migration.
• Identifying novel therapeutic targets and agents is critical for effective GBM treatment.
• Understanding the molecular mechanisms underlying GBM progression is essential.

Purpose of the Study:

• To investigate the inhibitory effects of Enhydrin on GBM cell destructive activities.
• To elucidate the molecular mechanisms and signaling pathways involved in Enhydrin's action against GBM.
• To evaluate Enhydrin as a potential therapeutic agent for GBM.

Main Methods:

• Network pharmacology and bioinformatics analysis were employed to identify key genes and pathways.
• In vitro and in vivo experiments were conducted to assess Enhydrin's efficacy.
• Molecular mechanisms involving gene expression and signaling pathway modulation were examined.

Main Results:

• Jun was identified as a key gene, and Epithelial-Mesenchymal Transition (EMT) as a critical signaling pathway.
• Enhydrin inhibits the Jun gene, leading to increased Smad7 expression.
• Smad7 down-regulates TGF-β1 and the Smad2/3 pathway, thereby hindering GBM cell EMT, proliferation, invasion, and migration.

Conclusions:

• Enhydrin effectively hinders GBM progression by targeting the Jun/Smad7/TGF-β1 signaling pathway.
• This mechanism significantly reduces GBM cell proliferation, invasion, and migration.
• Enhydrin shows considerable promise as a novel therapeutic agent for glioblastoma treatment.